Bile duct adenoma and small-sized small duct type intrahepatic cholangiocarcinoma show distinct differences in genetic alterations, expression of IMP3 and EZH2 and stromal and inflammatory components.
BRAF(V600E)
Intrahepatic cholangiocarcinoma
MTAP
bile duct adenoma
genetic alterations
small duct type
Journal
Histopathology
ISSN: 1365-2559
Titre abrégé: Histopathology
Pays: England
ID NLM: 7704136
Informations de publication
Date de publication:
Aug 2023
Aug 2023
Historique:
revised:
11
03
2023
received:
27
12
2022
accepted:
13
04
2023
medline:
10
7
2023
pubmed:
4
5
2023
entrez:
4
5
2023
Statut:
ppublish
Résumé
Given that bile duct adenoma was significantly more prevalent in the liver with small duct type intrahepatic cholangiocarcinoma (small duct iCCA), compared to other primary liver carcinomas, we examined the possibility of bile duct adenoma as a precursor of small duct iCCA by analysing genetic alterations and other features in bile duct adenomas. Subjects included 33 bile duct adenomas and 17 small-sized (up to 2 cm in diameter) small duct iCCAs. Genetic alterations were examined by direct sequencing for hot-spot regions and immunohistochemical staining. The expression of p16 Bile duct adenomas and small-sized small duct iCCAs show distinct differences in genetic alterations, expression of IMP3 and EZH2 and stromal and inflammatory components. There was no evidence suggesting that bile duct adenoma is a precursor of small duct iCCA. Immunohistochemical staining for IMP3, EZH2, p53, ARID1A and MTAP may be useful for differential diagnosis between bile duct adenomas and small duct iCCAs.
Substances chimiques
Tumor Suppressor Protein p53
0
EZH2 protein, human
EC 2.1.1.43
IGF2BP3 protein, human
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
298-309Subventions
Organisme : Ministry of Education, Culture, Sports and Science and Technology of Japan
Organisme : Shibuya Science Culture and Sports Foundation
Informations de copyright
© 2023 John Wiley & Sons Ltd.
Références
Nakanuma Y, Klimstra D, Komuta M, Zen Y. Intrahepatic cholangiocarcinoma. In Board WCoTE ed. WHO classification of tumours. Digestive system tumours. Lyon: IARC, 2019.
Sirica AE, Gores GJ, Groopman JD et al. Intrahepatic cholangiocarcinoma: continuing challenges and translational advances. Hepatology 2019; 69; 1803-1815.
Nakanuma Y, Sato Y, Ikeda H et al. Intrahepatic cholangiocarcinoma with predominant "ductal plate malformation" pattern: a new subtype. Am. J. Surg. Pathol. 2012; 36; 1629-1635.
Sempoux C, Kakar S, Kondo F, Schirmacher P. Combined hepatocellular-cholangiocarcinoma and undifferentiated primary liver carcinoma. In Board WCoTE ed. WHO classification of tumours. Digestive system tumours. Lyon: IARC, 2019.
Pinho AC, Melo RB, Oliveira M et al. Adenoma-carcinoma sequence in intrahepatic cholangiocarcinoma. Int. J. Surg. Case Rep. 2012; 3; 131-133.
Hasebe T, Sakamoto M, Mukai K et al. Cholangiocarcinoma arising in bile duct adenoma with focal area of bile duct hamartoma. Virchows Arch. 1995; 426; 209-213.
Song JS, Lee YJ, Kim KW, Huh J, Jang SJ, Yu E. Cholangiocarcinoma arising in von meyenburg complexes: report of four cases. Pathol. Int. 2008; 58; 503-512.
Jain D, Sarode VR, Abdul-Karim FW, Homer R, Robert ME. Evidence for the neoplastic transformation of von-meyenburg complexes. Am. J. Surg. Pathol. 2000; 24; 1131-1139.
Tsui W, Nakanuma Y. Bile duct adenoma. In Board WCoTE ed. WHO classification of tumours. Digestive system tumours. Lyon: IARC, 2019.
Sasaki M, Sato Y, Nakanuma Y. Bile duct adenoma may be a precursor lesion of small duct type intrahepatic cholangiocarcinoma. Histopathology 2021; 78; 310-320.
Sasaki M, Sato Y. An immunohistochemical panel of insulin-like growth factor ii mrna-binding protein 3 (imp3), enhancer of zeste homolog 2 (ezh2), and p53 is useful for a diagnosis in bile duct biopsy. Virchows Arch. 2021; 479; 697-703.
Sasaki M, Matsubara T, Kakuda Y, Sato Y, Nakanuma Y. Immunostaining for polycomb group protein ezh2 and senescent marker p16ink4a may be useful to differentiate cholangiolocellular carcinoma from ductular reaction and bile duct adenoma. Am. J. Surg. Pathol. 2014; 38; 364-369.
Sasaki M, Sato Y, Nakanuma Y. Cholangiolocellular carcinoma with "ductal plate malformation" pattern may be characterized by arid1a genetic alterations. Am. J. Surg. Pathol. 2019; 43; 352-360.
Theise ND, Nakashima O, Park YN, Nakanuma Y. Combined hepatocellular-cholangiocarcinoma. In Bosman FT, Carneiro F, Hruban RH, Theise ND eds. WHO classification of tumours of the digenstive system. Lyon: IARC Press, 2010; 225-227.
Hsu M, Sasaki M, Igarashi S, Sato Y, Nakanuma Y. Kras and gnas mutations and p53 overexpression in biliary intraepithelial neoplasia and intrahepatic cholangiocarcinomas. Cancer 2013; 119; 1669-1674.
Sasaki M, Yoneda N, Sawai Y et al. Clinicopathological characteristics of serum amyloid a-positive hepatocellular neoplasms/nodules arising in alcoholic cirrhosis. Histopathology 2015; 66; 836-845.
Angkathunyakul N, Rosini F, Heaton N, Foskett P, Quaglia A. Braf v600e mutation in biliary proliferations associated with alpha1 -antitrypsin deficiency. Histopathology 2017; 70; 485-491.
Sasaki M, Sato Y, Nakanuma Y. Mutational landscape of combined hepatocellular carcinoma and cholangiocarcinoma, and its clinicopathological significance. Histopathology 2017; 70; 423-434.
Sasaki M, Tsuneyama K, Ishikawa A, Nakanuma Y. Intrahepatic cholangiocarcinoma in cirrhosis presents granulocyte and granulocyte-macrophage colony-stimulating factor. Hum. Pathol. 2003; 34; 1337-1344.
Mao TL, Ardighieri L, Ayhan A et al. Loss of arid1a expression correlates with stages of tumor progression in uterine endometrioid carcinoma. Am. J. Surg. Pathol. 2013; 37; 1342-1348.
Chapel DB, Schulte JJ, Berg K et al. Mtap immunohistochemistry is an accurate and reproducible surrogate for cdkn2a fluorescence in situ hybridization in diagnosis of malignant pleural mesothelioma. Mod. Pathol. 2020; 33; 245-254.
Goeppert B, Frauenschuh L, Renner M et al. Braf v600e-specific immunohistochemistry reveals low mutation rates in biliary tract cancer and restriction to intrahepatic cholangiocarcinoma. Mod. Pathol. 2014; 27; 1028-1034.
Seto K, Haneda M, Masago K et al. Negative reactions of braf mutation-specific immunohistochemistry to non-v600e mutations of braf. Pathol. Int. 2020; 70; 253-261.
Sasaki M, Sato H, Kakuda Y, Sato Y, Choi JH, Nakanuma Y. Clinicopathological significance of ‘subtypes with stem-cell feature’ in combined hepatocellular-cholangiocarcinoma. Liver Int. 2015; 35; 1024-1035.
Zhang XF, Dong M, Pan YH et al. Expression pattern of cancer-associated fibroblast and its clinical relevance in intrahepatic cholangiocarcinoma. Hum. Pathol. 2017; 65; 92-100.
Jeon Y, Kwon SM, Rhee H et al. Molecular and radiopathologic spectrum between hcc and intrahepatic cholangiocarcinoma. Hepatology 2022; 77(1); 92-108.
Pujals A, Bioulac-Sage P, Castain C, Charpy C, Zafrani ES, Calderaro J. Braf v600e mutational status in bile duct adenomas and hamartomas. Histopathology 2015; 67; 562-567.
Augustin J, Calderaro J, Pujals A. Braf-associated bile duct adenomatosis: a new entity? Histopathology 2020; 77; 160-161.
Pujals A, Amaddeo G, Castain C et al. Braf v600e mutations in bile duct adenomas. Hepatology 2015; 61; 403-405.
Moeini A, Sia D, Bardeesy N, Mazzaferro V, Llovet JM. Molecular pathogenesis and targeted therapies for intrahepatic cholangiocarcinoma. Clin. Cancer Res. 2016; 22; 291-300.
Wardell CP, Fujita M, Yamada T et al. Genomic characterization of biliary tract cancers identifies driver genes and predisposing mutations. J. Hepatol. 2018; 68; 959-969.
Boerner T, Drill E, Pak LM et al. Genetic determinants of outcome in intrahepatic cholangiocarcinoma. Hepatology 2021; 74; 1429-1444.
Varela I, Tarpey P, Raine K et al. Exome sequencing identifies frequent mutation of the swi/snf complex gene pbrm1 in renal carcinoma. Nature 2011; 469; 539-542.
Sasaki M, Sato Y. Insulin-like growth factor ii mrna-binding protein 3 (imp3) is a marker that predicts presence of invasion in papillary biliary tumors. Hum. Pathol. 2017; 62; 152-159.
Girolami I, Lucenteforte E, Eccher A et al. Evidence-based diagnostic performance of novel biomarkers for the diagnosis of malignant mesothelioma in effusion cytology. Cancer Cytopathol. 2022; 130; 96-109.
De Jaeghere EA, Denys HG, De Wever O. Fibroblasts fuel immune escape in the tumor microenvironment. Trends Cancer 2019; 5; 704-723.